Cemiplimab Plus Chemotherapy Versus Chemotherapy in Advanced NSCLC: 5-year Results from Phase 3 EMPOWER-Lung 3 Part 2 Trial

Rapid Readouts

Rapid Readouts is a video program featuring leading experts who provide in-depth reviews of the most pivotal and practice-changing data that have been unveiled at recent medical oncology conferences. In each video, top oncologists in their specialty present slides and posters from these annual symposiums and meetings, while highlighting the ever-changing landscape of treatment choices for patient management.

Asher Chanan-Khan, MD, discusses an analysis from the ALPINE trial showing that zanubrutinib reduced the number needed to treat to avoid one progression or death compared with ibrutinib in relapsed/refractory chronic lymphocytic leukemia, with results also demonstrating substantial cost savings from a US payer perspective

Number Needed to Treat Analysis of Zanubrutinib in Relapsed/Refractory Chronic Lymphocytic Leukemia